Significant Improvements to Chimeric Antigen Receptor T Cell Therapies Lie Ahead
Share

Chimeric antigen receptor T cell (CAR-T) therapies have proven to be a promising advance in the state of the art when it comes to cancer immunotherapy, though there are certainly challenges remaining to be overcome. The real promise is not only the improved effectiveness, however, but rather that this technology platform offers the ability to treat many different cancers with only an incremental cost in adaptation to each new target.

Chimeric antigen receptor T cell (CAR-T) therapiesa promising advanceimmunotherapy

Over the long term, economics is the driver of success in cancer research. Given that there are hundreds of types of cancer and only so many scientists and only so much funding, the most important lines of research and development are those that can be cost-effectively turned to address many or all cancers. The defeat of cancer in our lifetimes requires universal therapies. CAR-T as a technology platform is now well enough known and proven to be attracting a great deal of interest in its evolution and improvement. This is now beginning to manifest in proof of principle results such as those noted here.

There have been few cancer treatments with such a promising future as using the patient’s own immune system. Known

read more...


Article originally posted at
www.fightaging.org

Click here for the full story


© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD